NCT01549054View on ClinicalTrials.gov

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2012

Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
DRUG

10-mg dose of E5501 2G tablet

Treatment A: Single 10-mg dose of E5501 2G tablet

DRUG

10-mg dose of E5501 cyclodextrin oral solution

Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution

DRUG

10-mg dose of E5501-P21% powder

Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension

DRUG

10-mg dose of E5501 lipid-based oral

Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension

Trial Locations (1)

Unknown

Quotient, Nottingham

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT01549054 - A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 | Biotech Hunter | Biotech Hunter